Cll Pharma

Synt : Em

Centre National De La Recherche Scientifique

Btg International Limited

Université´ D'aix-marseille

Vect-horus

Synt:em S.a.

Orphit

Jamal Temsamani

Claude Laruelle

Michel Kaczorek

Michel Khrestchatisky

Marion David

Roger Lahana

Pascaline Lecorche

Mark Elliott Johnson

Philippe Clair

Patrick Mouchet

Fiona Hamilton Day

Jonathan Nowak

Cédric Malicet

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

Compositions and methods for cancer imaging and radiotherapy

A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.

Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases

The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.

Use of the pat nanopeptide in the treatment of autoimmune diseases

The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.

Use of the PAT nanopeptide in treating and preventing neurodegenerative diseases

The invention concerns a pharmaceutical composition for treating and/or preventing cancer comprising at least an anti-cancer agent, characterised in that said anticancer agent is associated in the composition with at least a peptide capable of carrying said agent into the cancer cells and prevent the occurrence of chemoresistance to said agent.

Pharmaceutical composition comprising an anti-cancer and at least a peptide

The invention concerns the use of a linear peptide paired with an active substance for diagnosing or treating a CNS pathology by preparing a medicine capable of crossing the blood brain barrier to be used for diagnosis or treatment of a pathology localized in the CNS.

Peptides carrying substances across the blood brain barrier

The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.

Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses

The invention relates to conjugates of an antigen coupled to a linear derivative of a &#x3b2;-stranded antibiotic peptide, which are useful for immunogenic agents to enhance a CTL response. Two groups of preferred peptides are derived from the antibiotics protegrin and tachyplesin.

Growing community of inventors

Nimes, France

Jamal Temsamani